These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22936562)

  • 1. Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
    Kuramoto T; Inagaki T; Fujii R; Sasaki Y; Nishizawa S; Nanpo Y; Matusmura N; Kohjimoto Y; Hara I
    Int J Clin Oncol; 2013 Oct; 18(5):890-7. PubMed ID: 22936562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
    Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
    Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
    Nakai Y; Nishimura K; Nakayama M; Uemura M; Takayama H; Nonomura N; Tsujimura A;
    Int J Clin Oncol; 2014 Feb; 19(1):165-72. PubMed ID: 23456140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
    Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
    Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer.
    Laber DA; Chen MB; Jaglal M; Patel A; Visweshwar N
    Clin Genitourin Cancer; 2018 Dec; 16(6):473-481. PubMed ID: 30072309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
    Nishimura K; Nonomura N; Hashine K; Kanayama HO; Ozono S; Miura T; Miki T; Kakehi Y; Arai Y; Ogawa O; Fujita R; Nonomura K; Mizokami A; Hoshi S; Akaza H
    Int J Clin Oncol; 2013 Apr; 18(2):306-13. PubMed ID: 22350099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program.
    Lee JL; Park SH; Koh SJ; Lee SH; Kim YJ; Choi YJ; Lee J; Lim HY
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1005-13. PubMed ID: 25193433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer.
    Kongsted P; Svane IM; Lindberg H; Sengeløv L
    Clin Genitourin Cancer; 2016 Dec; 14(6):e559-e568. PubMed ID: 27102406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Shen Z; Yao Y
    J Cancer Res Clin Oncol; 2011 Dec; 137(12):1785-90. PubMed ID: 21915752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
    Nakano K; Ohta S; Komatsu K; Kubo T; Nukui A; Suzuki K; Kurokawa S; Kobayashi M; Morita T
    BMC Urol; 2012 Feb; 12():3. PubMed ID: 22353627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
    Song P; Huang C; Wang Y
    Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
    Picus J; Halabi S; Kelly WK; Vogelzang NJ; Whang YE; Kaplan EB; Stadler WM; Small EJ;
    Cancer; 2011 Feb; 117(3):526-33. PubMed ID: 20862750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
    Kobayashi K; Yokonishi T; Ito Y; Matsumoto T; Umemoto S; Osaka K; Nakamura M; Onuki T; Komiya A; Ohgo Y; Sakai N; Noguchi S; Kishi H; Yokomizo Y; Kawai M; Okajima K; Tajiri T; Fujikawa A; Ohta J; Yumura Y; Moriyama M
    Hinyokika Kiyo; 2010 Apr; 56(4):203-7. PubMed ID: 20448443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
    BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
    Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
    Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.